Skip navigation

Et tu, J&J?

I always think of Johnson & Johnson as one of the good guys, so it was very disheartening to read this article in the New York Times (free reg. req'd): Lucrative Drug, Danger Signals and the F.D.A. about its heartburn drug, Propulsid. A snip:

Propulsid's history has striking parallels with the painkillers now at the

center of controversy. Dozens of studies sponsored by Johnson & Johnson that

might have warned doctors away were never published, just as the pharmaceutical

manufacturer Pfizer

failed to publish an early study of Celebrex that indicated a heart risk. And

Johnson & Johnson was able to delay and soften some proposed label changes,

just as Merck

later did with Vioxx.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish